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Abstract. Nanoparticles, including lipopolyamines leading to lipoplexes, liposomes, and polyplexes are
targeted drug carrier systems in the current search for a successful delivery system for polynucleic acids.
This review is focused on the impact of gene and siRNA delivery for studies of efﬁcacy,
pharmacodynamics, and pharmacokinetics within the setting of the wide variety of in vivo animal
models now used. This critical appraisal of the recent literature sets out the different models that are
currently being investigated to bridge from studies in cell lines through towards clinical reality. Whilst
many scientists will be familiar with rodent (murine, fecine, cricetine, and musteline) models, few
probably think of ﬁsh as a clinically relevant animal model, but zebraﬁsh, madake, and rainbow trout are
all being used. Larger animal models include rabbit, cat, dog, and cow. Pig is used both for the prevention
of foot-and-mouth disease and human diseases, sheep is a model for corneal transplantation, and the
horse naturally develops arthritis. Non-human primate models (macaque, common marmoset, owl
monkey) are used for preclinical gene vector safety and efﬁcacy trials to bridge the gap prior to clinical
studies. We aim for the safe development of clinically effective delivery systems for DNA and RNAi
technologies.
KEY WORDS: efﬁcacy; gene delivery; pharmacodynamics; pharmacokinetics; RNAi.
INTRODUCTION
Gene therapy consists of the modiﬁcation of gene
expression for therapeutic gain; it is dependent on an
understanding of basic biological principles. In many, if not
most, gene therapy studies, a “corrected” gene is inserted into
the genome to replace an “abnormal” disease-causing gene
(Fig. 1). A carrier (a vector) must be used to deliver the
therapeutic gene to the patient’s target cells. The most
common vectors are viruses that have been genetically
altered to carry normal human DNA. All viruses attack their
hosts and introduce their genetic material into the host cell as
part of their replication cycle, and therefore they are used as
vehicles to carry “good” genes into a human cell. Numerous
problems exist that lessen the likelihood of success for gene
therapy using viral vectors: many undesired effects (the
vectors are often toxic or immunogenic), hard to ensure the
virus will infect the target cells in the body, and the inserted
gene must not disrupt any vital genes already in the genome.
However, companies persist with this method of gene
introduction.
There are also non-viral methods for gene therapy (1–4).
Although low levels of transfection and gene expression
mean that non-viral vectors are still less efﬁcient, they present
certain advantages over viral methods with simple large scale
production and low host immunogenicity being just two.
Recent advances in non-viral cationic lipid vector technology
have yielded molecules and techniques with transfection
efﬁciencies similar to those achieved with viruses. In modern
non-viral methods, plasmid DNA is coated with lipids in an
organized structure, as a lipoplex or polyplex (if from cationic
polymers, Fig. 2) (1–4), or small interfering RNA (siRNA) to
signal the cell to cleave speciﬁc sequences in the mRNA
transcript of the faulty gene, disrupting its translation and
therefore silencing expression of the gene (4,5).
In theory, the transformation of either somatic cells or
cells of the germ-line is possible. All gene therapy to date on
humans has been directed at somatic cells, whereas germ-line
engineering in humans (rightly) remains controversial. Over
the last two decades, gene transfer experiments for the
treatment of inherited or acquired diseases have been
performed. Gene therapy has moved from preclinical to
clinical studies for many diseases ranging from single gene
disorders such as cystic ﬁbrosis and Duchenne muscular
dystrophy, to more complex diseases such as cancer and
cardiovascular disorders (6). For a better understanding of
the structure and function of human genes, and to develop
new strategies in order to combat diseases, we should
compare the human genome with genomes of other organ-
isms, identifying regions of similarity and difference.
Comparative genome studies found that the DNA
sequence similarities with humans are about 70–90%
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(∼85%) the same in mice (http://www.ornl.gov/sci/techresour
ces/human_genome/faq/compgen.shtml), but with a lot of key
variations (e.g. some mouse and human gene products are
almost identical, while others are nearly unrecognizable as
close relatives), 75% in dogs (http://www.home.earthlink.net/
~blindworld2/index.htm), 71% in pigs (7). Cat and primate
share 73% of their genomes (8). Among the 768 known genes
of cattle, 638 (83%) could be identiﬁed as identical to human
genes (http://www.scienceblog.com/community). All rabbit
chromosome paints, except the Y paint, hybridized to human
chromosomes and all human chromosome paints, except the
Y paint, hybridized to rabbit chromosomes (9). Chimpanzee
DNA sequence is 98.8% identical to ours (http://www.
genome.gov). Fruit ﬂy genome and our human genome have
60% of genes in common (http://nes.bbc.co.uk). Also, we
share half our genes with a banana (http://www.wasdarwin
right.com/homology.htm)!
Animal models of human diseases are important in the
development and assessment of gene therapy. This is
particularly evident in the evaluation of gene therapy
Many copies are made
Normal allele is
cut out from donor
Normal allele (from ex-vivo) is put into the
cells of a person with the genetic disorder
Viral delivery or
Electroporation or
Direct injection of DNA
Fig. 1. The basic process of ex-vivo gene therapy.
Fig. 2. Non-viral gene therapy.
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protocols for clinical trials as gene transfer studies with
statistically and rationally meaningful outcomes need to be
evaluated in models that closely resemble human diseases.
Animal models clearly are an important step in the preclinical
evaluation of human-directed gene transfer protocols which
are not possible in humans for ethical and lack of volunteer
reasons (10,11).
RNA interference (RNAi) is already a recognized
functional genomics research tool for mammalian gene
knock-down studies, target discovery, and validation. It shows
great diagnostic and therapeutic potential (Fig. 3). Of course,
there could be huge commercial potential for gene therapy
products. For these reasons biotechnology and pharmaceuti-
cal companies are investing in the development of gene
therapy and RNAi technologies. It could reduce the time
needed for target validation and drug development, acceler-
ating the drug discovery process. RNAi-based screens pro-
vide new opportunities for the discovery and validation of
novel therapeutic targets in several disease areas e.g. cancer
and infectious diseases. A signiﬁcant effect of an oligonucle-
otide on the disease phenotype indicates that the target in
question plays an important role in the disease state. Potent
RNAi compounds can provide important tools for in vivo
validation and can be administered in animal models of
disease in order to determine if inhibition of expression
results in a corresponding in vivo change in the disease
phenotype (12). An RNAi knockdown model can be
produced in a fraction of the time and cost required for
previous antisense “knockout mouse” technologies, and so
(in remarkably short order) these have been largely replaced
by RNAi-based systems. The precise (selective) mechanism
of siRNA action reduces the potential for side-effects (few
off-target effects). Delivery and intracellular stability of
siRNA agents are the major hurdles (3–5,13–15).
Translation of emerging technologies into commercially
viable therapeutics involves a consideration of competing
technologies, safety, efﬁcacy, and regulatory issues (12).
RNAi therapeutics are being studied for the treatment of:
age-related macular degeneration (AMD), cancer, infections,
inﬂuenza, cardiovascular, CNS and metabolic disorders. More
speciﬁcally, these targets include: hypercholesterolemia, res-
piratory diseases, metabolic diseases, hepatitis C virus (HCV)
in the liver, liver cancers, and the p53 gene is targeted for the
treatment of renal failure. There is hope for the treatment of
neurodegenerative diseases: Parkinson’s disease and progres-
sive multifocal leukoencephalopathy (PML) which is caused
by infection of the CNS with “JC virus” and can occur in
immune-suppressed patients, including those receiving immu-
nomodulatory therapies. Targeting the Huntington’s disease
gene will be delivered by Medtronic’s implantable infusion
pump. So, will the technology be free of delivery problems
and safety issues? What accurate animal models exist to help
answer these important questions? We review ten different
animal models used to answer key questions about efﬁcacy,
pharmacodynamic (16,17) or pharmacokinetic (18,19) model-
ling prior to clinical trials.
ANIMAL MODELS
Gene therapy like any other administration of a new
drug has to be tested in animal models before clinical
application in humans. The early animal models for gene
therapy were focussed upon simulated inherited (genetic)
disorders, judged to be appropriate candidates for early
human trials and based heavily upon molecular medicine in
animals genetically engineered to reﬂect the disease state
(20–22). Transgenic animals are used to model different
human diseases: infection, neurodegeneration, apoptosis,
arteriosclerosis, ageing, cancer, xenografts, etc. (20–22). One
goal is to use these models to assess the potential efﬁcacy of a
genetic intervention by evaluating its impact on meaningful
surrogate or clinical endpoints.
Clearly, most of the gene transfer experiments have been
performed in mice. Large animal models, such as pigs or
horses, are almost exclusively used to study treatment of
induced diseases, cardiovascular disease and arthritis, respec-
tively (10,11). Sheep and non-human primates are used for
the development of gene transfer techniques, gene marking
studies, and assessment of safety, but despite the existence of
genetic diseases in these species, they have not yet been used
for treatment trials. However, aspects of the human popula-
tion that are impossible to simulate in animal models are the
tremendous environmental and genetic diversity. This will be
particularly important in the context of immune responses to
RNAi
miRNADiagnostics
(Small molecule)
Drug discovery
Therapeutics
Viral and
non-viral vectors
siRNA pDNA
Personalized medicine
Fig. 3. Genomics research tools.
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gene replacement therapy where several factors may pro-
foundly contribute to outcome, such as nature of mutations in
the disease gene, major histocompatibility genotype, and
previous exposure of the recipient to the delivery vehicle in
the context of naturally acquired infection.
Epstein Barr Virus (EBV), is associated with an
increasing number of lymphoid and epithelial malignan-
cies. Among the genes expressed by EBV during latency,
LMP1 plays a key role for growth transformation and
immortalization of B lymphocytes. In elegant studies, from
the Dept. of Public Health Sciences, University “La
Sapienza”, Rome, Galletti et al. (23), have shown that
antisense oligonucleotides (ONs) directed to LMP1 mRNA,
effectively suppressed LMP1 gene expression and substan-
tially reduced proliferation of the infected cells (using a
marmoset cell line). As the use of antisense phosphodiester
oligonucleotides as therapeutic agents is limited by inefﬁ-
cient cellular uptake and intracellular transport to the target
mRNA, they therefore tested the ability of three cationic
carriers internalized by different pathways, to increase the
delivery of anti-LMP1-ON to their site of action in EBV-
infected B lymphocytes. Liposomes, dendrimers or transfer-
rin-polylysine-conjugated ON were internalized by the cells
at an extent several-fold higher than that of the naked
oligomers. However, only the delivery system exploiting the
transferring-receptor mediated pathway was able to vector-
ize biologically active antisense LMP1-ON.
These cell line studies typify a lot of current pharmaceu-
tical research in non-viral gene therapy. Our own work on
DNA condensation and cell-line transfection is similarly
poised to make the transition in to animal models for target
diseases in gene therapy (1,4,24–30).
FISH MODELS
Few probably think of ﬁsh (piscine models) as a clinically
relevant animal model. However, zebraﬁsh (Danio rerio) (31–
33) and medaka (Oryzias latipes) (34–36) are used as initial
models of gene delivery and even as animal models of human
disease e.g. hepatic diseases and cancer (37). Rainbow trout
(Oncorhynchus mykiss) models (38) are also being used.
Zebraﬁsh is a good model for a better understanding of
congenital diseases, such as Achromatopsia, and campomelic
dysplasia or defects in neural crest development that are a
signiﬁcant cause of human disease.One of these isWaardenburg’s
Syndrome, a neurocristopathy in which individuals have domi-
nant pigmentation defects. Loss of speciﬁc cone types causes
partial colour blindness, whereas general loss of cone function
causes total colour blindness or macular degeneration (33).
Another is related to deafness. Medaka is a ﬁsh model for
studying the organogenesis process, haemoglobin-bilirubin me-
tabolism, and the function of Toll1 receptor (34–36). In rainbow
trout, adjuvant effects on the early response to a viral
hemorrhagic septicemia virus (VHSV) immunization has been
investigated. DNA vaccines against ﬁsh rhabdovirus (VHSV)
using expression plasmids coding for the viral glycoprotein
(pMCV1.4-G) co-administeredwith cloned interleukin 8 (pIL8+),
and speciﬁcally the route of delivery and the efﬁcient use of
adjuvants are under investigation (37).
RODENT MODELS
The importance of rodent (murine, fecine, cricetine, and
musteline) models for DNA and siRNA delivery strategies is
self-evident from their number. Murine (mouse and rat)
models depend on the assumption that their biological
processes very closely resemble those in humans. They are
also inexpensive to keep, their generation time is short, and
they have large litters. However, murine models may fail to
mirror faithfully the human diseases and longitudinal studies
are not possible because of their short lifespan. Thus, large
animal models of human genetic diseases complement murine
studies because they have a longer lifespan, are more similar
in size to a neonate or child, their background genetic
heterogeneity is similar to that of humans, and they are
genetically more closely related to humans than mice (10,11).
Mice are still used to study many different diseases e.g.
cancer, haemophilia, neurological diseases, SCID, Duchenne
muscular dystrophy and many others. These models provide
us with differentiated tissues, which are not often available
from human sources. Furthermore, they allow for testing the
effects of genetic manipulation and experimental therapeutics
on physiology and pathology. In Duchenne muscular dystro-
phy, the mutations in the dystrophin gene occur in the region
encoding the spectrin-like central rod domain. Splicing
around mutations can generate a shortened, but in-frame
transcript, thereby permitting translation of a partially
functional dystrophin protein. This was tested in vivo in the
dystrophic mouse, carrying a mutation in exon 23 of the
dystrophin gene. The treated mice showed persistent produc-
tion of dystrophin at normal levels in large numbers of muscle
ﬁbres with functional improvement of the treated muscle
(38).
The most common lethal genetic disease in the Cauca-
sian population is cystic ﬁbrosis (CF). CF is a monogenic
disease whose phenotype variability is attributed to genetic
variation in the “modiﬁer” genes. Several research groups
have interrupted or incorporated speciﬁc mutations into the
CF transmembrane conductance regulator gene (CFTR)
(39,40). Lethal gastrointestinal manifestations of the disease
were prevented by introducing into the germ line of a CF
mouse a transgene encoding human CFTR expressed from a
gut-speciﬁc promoter (39,40).
Several studies have demonstrated efﬁcient in vivo
delivery of siRNA (13–15). The ﬁrst direct delivery of siRNA
in vivo was carried out using the “hydrodynamic” technique
of administering naked siRNA in a large volume of a
physiological solution, under high pressure, into the tail vein
of mice. In order to evaluate the efﬁcacy of this delivery
method, mice were co-injected with plasmids expressing the
luciferase gene as a reporter along with synthetically pre-
pared siRNA targeted to the luciferase mRNA (Fig. 4) (41).
Most gene transfer experiments are performed in mice,
an early model for the switch from cell lines to in vivo (42).
Using hydrodynamic delivery (tail vein) to mouse, there is
recent evidence that siRNA is better than shRNA (encoded
by plasmid DNA) for in vivo knockdown (43). Liver ﬁbrosis,
induced by CCl4 or bile duct ligation, was ameliorated by
adenoviral gene transfer of (matrix metalloproteinase) MMP-
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8, human neutrophil collagenase, in rat models (44). Earlier,
adenoviral gene transfer with human urokinase-type plasmin-
ogen activator (uPA) also reversed experimental rat liver
ﬁbrosis inducing collagenase expression (45). So, gene
delivery of interstitial collagenases is promising for the
treatment of advanced cirrhosis in humans. However, persis-
tent overexpression of interstitial collagenases in the liver
possibly digests normal architectures in addition to patholog-
ically deposited ECM. Therefore, precisely controlled deliv-
ery of active interstitial MMPs may be necessary for
developing a clinical treatment (46).
With regard to treating genetic blindness, an animal model
of Leber congenital amaurosis (LCA), the Lrat−/− mouse, has
the clinical features of this human disease. Intraocular injected
rAAV-delivered Lrat gene therapy and oral pharmacological
treatment with novel 9-cis-retinyl acetate and 9-cis-retinyl
succinate, which are easier to synthesize and more stable
than the 11-cis-isomers they replaced, successfully restored
electroretinographic responses to ∼50% of wild-type levels
(p<0.05 versus wild-type and knockout controls), and pupillary
light responses of Lrat−/− mice also increased ∼2.5 log units
(47).
The therapeutic utility of cytochrome P450-based en-
zyme pro-drug therapy is well established by preclinical
studies and in initial clinical trials. The underlying premise
of this gene therapy is that intratumoural P450 expression
leads to in situ activation of anticancer P450 pro-drugs, such
as cyclophosphamide (CPA), with intratumoural accumula-
tion of its activated 4-OH metabolite and favourable phar-
macokinetics as shown in mice bearing 9L gliosarcomas (a
subcutaneous solid tumour an in vivo model for inoperable
pancreatic carcinoma) expressing P450 2B11, but not P450
2B6. Therefore, there is an advantage in gene therapy
strategies that combine low Km P450 pro-drug activation
enzymes with slow, localized release of P450 pro-drug
substrates. This recent work of Waxman and colleagues at
Boston University followed their report in 2000 of a
pharmacokinetic study of P450 reductase and CPA activation
in a rat cancer gene therapy model (48,49).
To establish non-viral gene delivery systems for intrave-
nous administration, complexes of pDNA and PLL and PEI
block copolymer were tested in in vivo turnover studies. The
polyion complex micelles have self-assembling core-shell
structures, yielding spherical nano-particles which were
administered i.v. into male balb/c mice as part of a pharma-
cokinetics study in cardiovascular research. Though having no
targeting ligands, these micelles efﬁciently transfected HepG2
cells. When the micelles were injected via the supramesen-
teric vein, expression of the gene was observed only in the
liver and this was sustained for 3 days. It was concluded that
this gene delivery system is intrinsically efﬁcient (50).
Interleukin-2 (IL-2) immunotherapy is a potent treat-
ment for cancer, but dangerous side-effects stand in the way
of its progress. A pharmacokinetics and safety evaluation,
using mice and cynomolgus monkeys, was performed with a
lipoplex encoding human IL-2 by Norman, Parker, and
colleagues at Vical in support of phase I human cancer
therapy clinical trials (51,52).
Kissel and co-workers in the Department of Pharmaceutics
and Biopharmacy (53), Marburg, have long being studying PEI
in order to make DNA polyplexes which efﬁciently show DNA
condensation, measured in the ethidium bromide ﬂuorescence
quenching assay which we optimized (54). They have com-
pared transfection efﬁciency results in various different cell
lines with pharmacokinetics and biodistribution in mice, where
approximately half of the injected dose accumulated in the
liver. They demonstrated that low molecular weight PEI is
better (less toxic and higher transfection efﬁciency) than PEI
of high molecular weight (53).
RNAi can knock down oncogenes in cancer, including
brain cancer, but the therapeutic potential of RNAi will not
be realised until the rate-limiting step of delivery is solved.
The view in 2004 was that “development of RNA-based
therapeutics is not practical, due to the instability of RNA in
vivo. However, plasmid DNA can be engineered to express
short hairpin RNA (shRNA), similar to endogenous micro-
RNAs.” A new i.v. non-viral RNAi-based gene therapy, with
a new gene-targeting technology, encapsulates the pDNA
inside receptor-speciﬁc pegylated immunoliposomes (PILs).
The feasibility of this RNAi approach was evaluated by
showing it was possible to achieve a 90% knockdown of brain
tumour-speciﬁc gene expression with a single intravenous
injection in adult mice and rats with intracranial human brain
cancer. The survival of these mice was extended by nearly
90% with weekly intravenous injections of PILs carrying
pDNA expressing a shRNA directed against the human
epidermal growth factor receptor. So, RNAi-based gene
therapy can be coupled with gene therapy that replaces
mutated tumour suppressor genes to build a polygenic
approach to the gene therapy of cancer (55).
Adenoviruses (Ad) are robust gene delivery vectors in
vivo, but are limited by their propensity to provoke strong
innate and adaptive responses. PEG modiﬁcation (with SPA-
PEG) of adenovirus can protect the vectors from pre-existing
and adaptive immune responses by reducing protein-protein
interactions and interactions with immune cells. Note that
Fig. 4. Monitoring luciferase inhibition in vivo using bioluminescent
imaging. The images of nude mice injected with 3×106 PC-3M-luc-C6
cells into the left ventricle of the heart. Four weeks after tumour
injection, each animal was administered with luciferase GL3 siRNA
complexed with 0.05% atelocollagen. On the next day, the
bioluminescent signals of most of the metastatic sites were inhibited
by 80–90% in the whole body (41). Reprinted with permission (41).
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while increasing PEGylation of Ad vectors ablated in vitro
transduction, it surprisingly had no negative effect on the
level or distribution of in vivo gene delivery, possibly via
heparin sulfate and integrin interactions. So, PEGylation can
reduce innate immune responses without reducing transduc-
tion in vivo. Non-speciﬁc vector uptake by macrophages and
Kupffer cells may be critically involved in the initial activation
of innate immune responses (56,57).
Early studies (1999) used direct injection for Ad-
mediated gene delivery in guinea pig (fecine) models (58).
Ad-mediated delivery of RNAi has also recently afforded
new anti-foot-and-mouth data in both guinea pig and pig. In
comparative studies, male and female guinea pigs (250 to
300 g) and large white swine (2- to 3-months-old, 40 to 50 kg)
were used to perform the viral challenges (59).
Gerbil and hamster (cricetine) models are also being
used. Ad-mediated gene transfer of ﬁbroblast growth factor-2
increases BrdU-positive cells after forebrain ischemia in
gerbils (60) and Ad-mediated overexpression of a gene
prevented hearing loss and progressive inner hair cell loss
after transient cochlear ischemia in gerbils (61). rAAV types 2
and 5 showed distinct patterns of gene transfer to gerbil
hippocampus (62), and rAAV-transduced vascular endothelial
cells express the thrombomodulin transgene under the
regulation of enhanced plasminogen activator inhibitor-1
promoter in Mongolian gerbils (63).
When type 1 protein phosphatase (PP1) is overactivated
in the failing heart, there is a depression of cardiac function.
In vivo PP1 inhibition by myocardial gene transfer of
inhibitor-2 (INH-2), an endogenous PP1 inhibitor, alleviates
heart failure (HF) progression in the cardiomyopathic
hamster, a well-established HF model (64). AAV-mediated
INH-2 gene delivery improved fractional shortening of the
left ventricle accompanied by reduced chamber size at 1
week. AAV-mediated INH-2 gene delivery signiﬁcantly
extended the survival time for 3 months. These results
provide a potential new treatment for HF without activating
protein kinase A signalling in cardiomyocytes (64). The limb
girdle muscular dystrophies (LGMD) are a genetically and
phenotypically heterogeneous group of degenerative neuro-
muscular diseases. A subset of the genetically recessive forms
of LGMD are caused by mutations in the four muscle
sarcoglycan genes (alpha, beta, gamma, and delta). The
coding sequences of all known sarcoglycan genes are smaller
than 2 kb, and thus can be readily packaged in rAAV-vectors
for efﬁcient delivery in a hamster model (Bio 14.6) after a
single intramuscular injection. These results support the
feasibility of rAAV-vector mediated delivery to treat LGMD
by direct in vivo gene transfer (65).
In early studies (1994), ferret (musteline) models were
used to show protection against inﬂuenza challenge in DNA
vaccination against haemagglutinin with a gene gun for
delivery of DNA-coated gold particles (66). More recently,
Engelhardt and co-workers reported the comparative biology
of rAAV transduction in ferret, pig, and human airway
epithelial cells as well as improving the related animal models
(67).
RABBIT MODELS
Familial hypercholesterolemia (FH) is an inherited disor-
der in humans caused by a deﬁciency of low density lipoprotein
receptors (LDLR). Rabbit (lapine) models (Watanabe Heri-
table Hyperlipidemic) were used as a model for FH in order to
develop an approach for liver-directed gene therapy based on
transplantation of autologous hepatocytes that were genetical-
ly corrected ex vivo with recombinant retroviruses. Rabbits
transplanted with LDLR-transduced autologous hepatocytes
demonstrated a 30–50% decrease in total serum cholesterol
that persisted for the duration of the experiment. Recombi-
nant-derived LDLR RNA was harvested from these tissues
with no diminution for up to 6.5 months after transplantation
(68).
Rabbits are also used in the study of heart diseases.
Using a percutaneous catheter-based approach and selective
intracoronary artery delivery in adult (New Zealand) rabbits,
various procedures were tested to optimize adenovirus-
mediated gene transfer efﬁciency, including pharmacological
pre-treatment to increase vessel permeability, transient inter-
ruption of coronary ﬂow, high-pressure delivery, and coro-
nary venous sinus occlusion (69). Other studies were aimed at
constructing a recombinant plasmid pcDNA3.1-VEGF165, to
observe the effect of vascular endothelial growth factor 165
(VEGF165) gene therapy on bone defects in New Zealand
white rabbits (Oryctolagus cuniculus) (70). The plasmid was
injected into the injured site in one of the forelegs with bone
defect as the experiment group. Physiological saline solution
was injected into the opposite foreleg as the control group. At
1, 2, 4, 6, 8, and 12 weeks after the operation, X-rays were
taken to observe the repair and healing of the bone defects
(Fig. 5). The VEGF165 mRNA was expressed at low level at
week 2, reached the peak at week 4 and then decreased a
normal level after 6 weeks. At 12 weeks, bone healing and
new bone were observed (70).
Fig. 5. X-ray of rabbit bone defects (70). Reprinted with permission of Chinese Medical Journal.
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Heme oxygenase-1 (HO-1) is a sensitive and reliable
indicator of cellular oxidative stress. There are beneﬁcial
therapeutic applications of human HO gene transfer and gene
therapy in a variety of clinical circumstances. The HO gene
must be delivered in a safe vector, adenoviral, retroviral or
leptosome based vectors are currently being used in clinical
trials. With the exception of HO gene delivery to either
ocular or cardiovascular tissue via catheter-based delivery
systems, HO delivery must be site and organ speciﬁc. This has
been achieved in rabbit ocular tissues, rat liver, kidney and
vasculature, and spontaneously hypertensive rat (SHR)
kidney (71).
FELINE MODELS
Cats are of particular interest for neurological disorders
and their brains have been well characterized both function-
ally and physiologically. The anatomy of the cat brain is
similar to that of a human. Lysosomal storage diseases are
good candidates for CNS gene therapy, because active
enzyme from genetically corrected cells can be secreted and
taken up by surrounding diseased cells, and only small
amounts of enzyme (<5% of normal) are required to reverse
storage lesions (72–74). Gene therapy was evaluated in brains
of cats affected with α-mannosidosis (AMD), a lysosomal
storage disease caused by a deﬁciency of lysosomal α-
mannosidase (LAMAN) activity via the AAV1-fMANB
vector (72). The disease in the cat is caused by a 4 bp
deletion in the feline α-mannosidase gene (fMANB) and is
characterized by clinical signs, neuropathology, and biochem-
ical abnormalities similar to those seen in human patients
(75).
Magnetic resonance imaging (MRI) was performed on
anesthetized cats (76–78). Treated cats showed the signal
intensity of the cerebral white matter to be reduced (Fig. 6)
(72). However, an improvement in cellular storage even at
large distances from the transduction sites was seen. Perhaps
due to diffusion of small quantities of LANAM from the
injection site in distant brain regions or an alternate method
of enzyme distribution, such as axonal transport or circulation
through the cerebrospinal ﬂuid (79–82).This study shows that
somatic gene transfer to the CNS can deliver functioning
enzyme directly to deﬁcient brain cells without the high
morbidity and mortality rates associated with bone marrow
transplantation (83,84).
CANINE MODELS
Over 50% of genetic diseases present in the dog are true
orthologues of human diseases caused by mutation in the
same genes. In addition to the obvious longevity and
similarity in size to a small child, many parts of the canine
immune system are similar to those of the human (85).
Mucopolysaccharidosis VII (MPS VII, Sly syndrome, β-
glucuronidase deﬁciency) is an inherited lysosomal storage
disorder caused by deﬁciency of β-glucuronidase activity,
required for the catabolism of glycosaminoglycans whose
accumulation in CV cells leads to cardiac disorders and also
to CNS diseases. Haskins, Wolfe, and their co-workers, at the
University of Pennsylvania, are making major contributions
in this research area (86–91). The ﬁrst animal model of MPS
VII was described in German Shepherd dogs. The cDNA
sequences are known and the mutation has been identiﬁed.
Some experiments tested intravenous retroviral (RV) vectors
in neonatal dogs at days 2–3 of life (86). There was a
signiﬁcant improvement in the growth of treated dogs, and
the skeletal disease was treated in their limbs (86). At 7 weeks
of age the percent of normal enzyme activity in peripheral
white blood cells containing vector sequence was very low
compared to the neonatally treated dogs, which may help
explain the beneﬁt of the earlier treatment (87–91).
Hemophilia A and B have also been studied in dogs.
They are x-linked inherited bleeding disorders caused by a
deﬁciency of the blood clotting factor in response to bleedings
crises. The canine models of haemophilia are useful for
developing and evaluating gene therapies because the canine
proteins are very well characterized, the genes have been
cloned, and cDNAs are available (92,93). Although vector-
associated toxicity (Fig. 7) remains an obstacle, a single
injection of HDV led to long-term transgene expression and
vector persistence in two FVIII-deﬁcient animals with con-
version of their severe phenotype to a moderate one (94).
The overall biological behaviour of malignant melanoma
is very similar in dogs and in humans. Therefore, the dog is an
ideal model for developing a therapy against these cancers. In
a trial for canine oral melanoma, liposomes conjugated to
Fas-ligand DNA were injected directly into the tumours to
induce apoptosis (95). Tumour regression of 12–58% was
observed in three of ﬁve treated dogs. No local or systemic
adverse effects were observed over the course of the
observation period (95–99) (Fig. 8).
Complete and reliable inﬁltration of the entire prostate is
important to improve the efﬁcacy of intraprostatic gene
therapy, as well as drug delivery. The optimal injection
scheme and feasibility of magnetic resonance imaging
(MRI) was evaluated in an orthotopic canine model. MRI
using gadolinium-diethylenetriamine pentaacetic acid is an
excellent modality to evaluate the effective volume distribu-
tion of injectate in an in vivo orthotopic prostate model (100).
Leber congenital amaurosis (LCA), a heterogeneous
early-onset retinal dystrophy, accounts for ∼15% of inherited
congenital blindness. One cause of LCA is loss of the enzyme
lecithin/retinol acyl transferase (LRAT), which is required for
regeneration of the visual photopigment in the retina. LCA
and early-onset severe retinal dystrophy (EOSRD) are
genetically heterogeneous, (retinal pigment epithelium)
RPE65 gene defects. LCA causes near total blindness in
infancy. A naturally occurring animal model, the RPE65−/−
dog, suffers from early and severe visual impairment similar
to that seen in human LCA. After gene therapy to correct
this RPE65 genetic defect, the dogs were able to walk
through a maze, demonstrating improved vision. So, visual
function was restored in this animal model of childhood
blindness with rAAV delivery of wild-type RPE65 (AAV-
RPE65) (101). Of all the diseases with a genetic component,
many scientists will be concerned about going blind. Can this
be cured? Outstanding work, by Ali, Bainbridge, Moore, and
colleagues at Moorﬁelds Eye Hospital and in the Division of
Inherited Eye Disease, UCL, is making real progress here
(102). This is possibly the most clinically advanced topic
covered in this review. The ﬁrst gene therapy eye trial in
humans with early onset retinal dystrophies as a result of
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mutations in RPE65 has now started, and the successful
results of the ﬁrst three adult patients were presented this
month; there are plans to enrol eight more patients this year
(103). If this is successful, treatment of other genetic disorders
such as LRAT deﬁciency will follow. The work in humans will
eventually make it into a refereed paper, but this week
(28.04.08) it was front-page stories in three major UK
newspapers, “Steven Howarth, 18, from Bolton, recovered
his sight enough to walk home at night”. True peer review.
BOVINE MODELS
Calves weigh about 30–35 kg at birth, similar to the
weight of a child, making them a good model to address
scaling-up issues for therapies designed for older children.
They are used as models of urea cycle defects like citrullin-
emia, a primary cause of hyperammonemia in the pediatric
population and are associated with very high neurologic
morbidity (Figs. 9 and 10) and mortality. Citrullinemia is
Fig. 7. Toxicity proﬁles in two hemophilic treated dogs. A aspartate aminotransferase and B alanine
aminotransferase analyses of three dogs receiving either 1·1012 vp kg−1 (dog A) or 3·1012 vp kg−1 (dogs B
and C) HDV on day zero. C Platelet levels were measured for each dog throughout vector administration
(94). Reprinted with permission (94).
Fig. 6. Normalization of magnetic resonance imaging in adeno-associated virus serotype 1 vector-feline α-mannosidase gene (AAV1-fMANB)-
treated cats. Transverse images of the cerebrum at the level of the thalamus in 16-week-old cats are shown (72). Copyright (2005) American
Neurological Association; reprinted with permission of John Wiley & Sons, Inc.
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caused by a nonsense mutation (C to T transition) in the gene
coding for arginosuccinate synthetase in cattle (104). Although
many of the clinical signs can be controlled by dietary restriction
of protein, additional illness can easily result in hyperammon-
emia. For these studies of urea cycle defects two neonatal calves
received an E1a-deleted adenovirus containing the human
arginosuccinate synthetase cDNA intravenously. A week after
administration of the adenovirus, both calves had elevated
serum aspartate-amino-transferase concentrations whilst all
other liver parameters remained normal at all time points (105).
PIG MODELS
Gene therapy could be a good antiarrhythmic strategy.
Arrhythmia is an abnormal heartbeat of any type: too fast,
too slow or just irregular. The heart can handle a few minutes
of accelerated heartbeat, but repeated episodes can cause
heart failure when the heart is simply too weak to pump
blood properly, and this can lead to dizziness, collapse or
death (106). A genetic modiﬁcation of the atrioventricular
node was investigated in an intracoronary perfusion model of
heart arrhythmias in pigs for gene therapy. Using this method,
porcine hearts were infected with Adβgal (rAd expressing
Escherichia coli β-gal) or with AdGi. (Ad encoding the Gαi2
subunit).
The hypothesis was that an excess of Gαi would mimic
the effects of β-adrenergic antagonists, in effect creating a
localized β-blockade. Gαi overexpression suppressed baseline
atrioventricular conduction and slowed the heart rate during
atrial ﬁbrillation without producing complete heart block. In
contrast, expression of the reporter gene β-galactosidase had
no electrophysiological effects. One week after treatment the
Fig. 9. Electron micrograph of the grey matter of the cerebral cortex of a
citrullinemia-affect calf demonstrating edema of the cytoplasm of
astroglial cells and their process (104). Reprinted from Harper et al. (104).
Fig. 8. a Effect of FasL gene therapy in a dog with oral melanoma. b Fas mRNA expression in tumours
from dogs treated with FasL gene. Fas expression was examined by RT-PCR. The expression of β-actin was
used as a loading control for the reactions and to ensure integrity of the RNA (95). Reprinted by permission
from Macmillan Publishers Ltd: Cancer Gene Therapy (95); copyright (2003).
Fig. 10. Light micrograph of the grey matter of the cerebral cortex of
citrullinemia-affected calf that demonstrates spongy change with
expansion of perivascular spaces, and astroglial cell processes (104).
Reprinted from Harper et al. (104).
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animals were killed and the organs were removed for
histological evaluation (Fig. 11) (107,108).
Differences between rodent and human airway cell
biology have made it difﬁcult to translate recombinant
adeno-associated virus (rAAV)-mediated gene therapies to
the lung for cystic ﬁbrosis (CF). As new ferret and pig models
for CF become available from Engelhardt and co-workers
(67), knowledge about host cell/vector interactions in these
species will become increasingly important for testing poten-
tial gene therapies. N-Linked sialic acid receptors were
required for rAAV1 and rAAV5 transduction of human and
mouse airway epithelia, but not ferret or pig airway epithelia.
Hence, although the airway tropisms of rAAV serotypes 1, 2,
and 5 are conserved better among ferret, pig, and human as
compared to mouse, viral receptors/co-receptors appear to
maintain considerable species diversity (67).
Pigs are used not only in medicines research and
development (59), but also for a new plasmid-mediated
approach to supplement pig somatotropin production as
reported by workers at ADViSYS in Texas (109). Ad-
mediated gene transfer of hyperpolarization-activated, cyclic
nucleotide-gated cation channels (HCN4) creates a genetic
pacemaker in pigs with complete atrioventricular block,
searching for a cure by site-speciﬁc gene therapy for
experimental cardiac bradyarrhythmia (110). Hydrodynamic
gene delivery is an attractive option for non-viral liver gene
therapy, but this approach requires evaluation of efﬁcacy,
safety, and clinically applicable techniques in large animal
models. Fabre et al. evaluated retrograde delivery of DNA to
the whole liver via the isolated segment of inferior vena cava
(IVC) draining the hepatic veins, using pigs (18–20 kg) that
were given pGL3 via two programmable syringe pumps in
parallel with interspecies comparison in rats. The hydrody-
namic procedure generated intrahepatic vascular pressures of
101–126 mmHg, which is approximately four times higher
than in rodents, but levels of gene delivery were approxi-
mately 200-fold lower. This is a clinically acceptable approach
to liver gene therapy. However, it is less effective in pigs than
in rodents, possibly because of larger liver size or a less
compliant connective tissue framework (111).
A cornerstone for an efﬁcient cardiac gene therapy is the
need for a vector system, which enables selective and long-
term expression of the gene of interest. In rodent animal
models, AAV vectors like AAV-6 have been shown efﬁciently
to transduce cardiomyocytes. However, since signiﬁcant
species-dependent differences in transduction characteristics
exist, large animal models are of imminent need for
preclinical evaluations. Raake and co-workers compared
gene transfer efﬁciencies of AAV-6 and heparin binding
site-deleted AAV-2 vectors in a pig model by pressure-
regulated retroinfusion of the anterior interventricular cardi-
ac vein, which has been previously shown to deliver genes
efﬁciently to the myocardium (3.5×1010 viral genomes per
animal). All vectors had a luciferase reporter gene under
cytomegalovirus (CMV)-enhanced 1.5 kb rat myosin light
chain promoter (CMV-MLC2v) control. There was
substantial increased reporter gene expression in the
targeted distal left anterior descending (LAD) territory.
Retroinfusion of AAV-2 vectors showed lower transgene
expression which could be increased with coadministration
of recombinant human VEGF. Signiﬁcant transgene
expression was not detected in other organs than the heart,
although vector genomes were detected also in the lung and
liver. Thus, they showed efﬁcient long-term myocardial
reporter gene expression in the targeted LAD area of the
porcine heart (112).
Genetic modiﬁcation of cells and animals is an invaluable
tool for biotechnology and biomedicine. Workers in the
Fig. 11. Measurement of gene transfer efﬁcacy. a X-gal staining of a transverse section through the AV groove. Cells expressing β-gal are
stained blue. b Western blot of AV nodal tissue demonstrates Gαi2 overexpression in the AdGi infected animals. c Gross and microscopic
pathology after exposure of liver, kidney and ovary to X-gal solution (107). Reprinted by permission from Macmillan Publishers Ltd: Nature
Medicine (107), copyright (2000).
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Department of Surgical Sciences, University of Milano,
recently reported their results on genetically modiﬁed pig
foetuses, delivered to embryos by the sperm-mediated gene
transfer method. As integrating vectors may lead to inser-
tional mutagenesis and variable transgene expression, and
they can undergo silencing, non-viral vectors are preferred.
Scaffold/matrix attachment region-based non-viral expression
systems (pEPI), that replicate autonomously in mammalian
cells, may enable safe and reliable genetic modiﬁcation of
higher eukaryotic cells and organisms. Their results, and the
important absence of mosaicism, are an important step
forward in animal transgenesis for biomedical applications
and might provide a basis for the future development of
germ-line gene therapy (113).
Pilling and co-workers in safety assessment studies at
GSK, Ware, reported particle-mediated DNA delivery for
DNA vaccination against hepatitis B in minipigs, determining
toxicity (there were a small number of phagocytosed gold
particles) and biodistribution of the pDNAwhich was present
and day 57 and by day 141 had cleared. The minipig is
regarded as a good model for humans so their data support
the hypothesis that particle-mediated DNA delivery will be
safe in human clinical applications (114).
Pigs and rhesus macaques are good models for efforts to
improve DNA vaccination immune potency and gene deliv-
ery. In electroporation studies of pDNA delivery to target
tissues, namely the skin. Hirao et al. in the School of
Medicine, University of Pennsylvania, studied the effect of
electroporation with high plasmid concentrations resulting in
improved gene expression for pGFP delivered by the
intradermal/subcutaneous (ID/SQ) route. In a macaque
model, they observed higher cellular and humoral responses
to an HIV DNAvaccine, which included plasmid-encoded IL-
12, with electroporation compared to ID/SQ injection alone.
The induced responses were TH1 mediated. Therefore, skin
electroporation may be important as an immunization
approach in larger animal models (115).
Pigs are also used for xenotransplantation. Pigs are
regarded as the next-best source of replacement organs
because porcine organs are similar in size to their human
counterparts. However, the human immune system recognises
pig organs as foreign. Recently, these problems have been
addressed by the genetic modiﬁcation of pigs to alter the
antigens displayed on the cell surface. One of the major
barriers to pig-human organ transplants is a particular type of
sugar molecule, Gal-α(1,3)-Gal, which is added to proteins on
the surface of pig cells but not human cells. Attempts have
been made to reduce the amount of this sugar by expressing
antibodies against it, inhibiting the enzyme α(1,3)-galactosyl-
transferase that is only present in pigs, or using additional
enzymes to modify it (116).
SHEEP MODELS
Lehn and co-workers reported transfection of foetal
sheep airways in utero using guanidinium-cholesterol cationic
lipids (117). Gene therapy, to reduce rejection-mediated
damage, holds out some promise as a novel therapeutic
strategy in corneal transplantation as the donor cornea can
easily be manipulated, ex vivo, prior to transplantation (118).
The corneal endothelium is the major target in human
corneal graft rejection. As these cells are essentially post-
mitotic, any such damage cannot be repaired through cell
division. The sheep is a useful model in this respect, as ovine
endothelial cells are amitotic. In the absence of topical
immunosuppression, corneal allografts become spontaneously
vascularized and undergo irreversible rejection at 3 weeks
postoperatively in a manner that is clinically and histological-
ly similar to human corneal graft rejection and therefore
particularly useful (118).
EQUINE MODELS
The horse is a good model for osteoarthritis as the
disease occurs naturally in this species. Osteoarthritis (OA) in
horses and in humans is a signiﬁcant social and economic
problem (119).
Adenoviral-mediated gene transfer was used to investi-
gate the therapeutic effects resulting from intra-articular
overexpression of the equine interleukin-1 receptor antagonist
gene in an established model of equine osteoarthritis that
mimics clinical osteoarthritis. In vivo delivery of the equine
IL-IRa gene led to elevated intra-articular expression of
interleukin-1 receptor antagonist for approximately 28 days,
resulting in signiﬁcant improvement in clinical parameters of
pain and disease activity, preservation of articular cartilage,
and beneﬁcial effects on the histological parameters of
synovial membrane and articular cartilage (120). In horse,
an osteochondral fragment was created in one randomly
selected intercarpal joint, to produce an experimental OA,
and the opposite joint served as the control (Fig. 12).
Fourteen days after surgery, they received Ad-EqIL-1Ra
viral particles/joint diluted with Gey’s balanced salt solution
(GBSS) in their joint with a lesion, while the opposite non-
fragmented joint received a similar volume of GBSS. Clinical
examination of the horses showed that the therapeutic
expression of IL-1Ra signiﬁcantly decreased signs of joint
pain as measured by degree of lameness (120).
NON-HUMAN PRIMATE MODELS
Non-human primate models for preclinical gene vector
safety and efﬁcacy trials are performed in a macaque model
(51,52), rhesus macaque (Macaca mulatta), in the owl monkey
(Aotus trivirgatus), and the common marmoset (Callithrix
jacchus).M. mulatta is an important model for human disease
research. Affymetrix GeneChip® Rhesus Macaque Genome
Array allows simultaneous interrogation of over 47,000 M.
mulatta transcripts.
siRNAs can be used together with hematopoietic stem cell
transplants stably to modulate gene expression in non-human
primates and therefore potentially to treat blood diseases e.g.
HIV-1 (121). The HIV-1 coreceptor, (C-C motif) chemokine
receptor 5 (CCR5), was selected as a model to examine the
feasibility of long-term and stable down-regulation of cellular
target gene by siRNA. CCR5 is an ideal target because it is
essential for infection by most strains of HIV-1 and it is
dispensable in normal humans. Down-regulation of CCR5 by
siRNA was demonstrated to protect primary human T
lymphocytes in culture from CCR5 tropic HIV-1 infection.
Although effective inhibition of HIV-1 infection was observed,
cytotoxicities in T lymphocytes correlated with CCR5 siRNA
11Animal Models for Target Diseases in Gene Therapy
expression levels. However, by using the weaker H1 promoter,
rather than the U6 promoter to express shRNA reduced
toxicities, the potency of the siRNAs was also attenuated (121–
123). Importantly, apparent adverse effects were not observed
from the use of lentiviral-mediated siRNA delivery on
hematopoietic stem cell differentiation, T cell levels, subset
phenotypes, or by gross measures of lymphocyte activation
(124,125).
In efforts to improve DNA vaccine immune potency,
electroporation has emerged as a method for pDNA delivery
to target tissues. However, few studies have examined the use
of this technology to deliver plasmid vaccines to the skin. As
detailed above, Hirao et al. reported121 the effects of
electroporation on DNA vaccine potency and gene delivery
using skin as a target tissue in a pig and a macaque model by
the intradermal/subcutaneous route.
Working in experimental psychology at the University of
Cambridge, Eslamboli et al. are investigating the therapeutic
potential of glial cell line-derived neurotrophic factor
(GDNF) for Parkinson’s disease using rAAVs expressing
GDNF as a delivery system in the common marmoset.
Efﬁcacy is likely to depend on sustained delivery of a
therapeutic amount to target areas without affecting the
function of the normal dopamine (DA) neurons. Unilateral
intrastriatal injection of rAAV resulting in the expression of
low levels of GDNF (0.04 ng/mg of tissue) provided
approximately 85% protection of the nigral DA neurons
and their projections to the striatum in the 6-OHDA-lesioned
hemisphere. When delivered continuously, a low level of
GDNF in the striatum (approximately threefold above
baseline) is sufﬁcient to provide optimal functional outcome
(126).
The owl monkey (A. trivirgatus) has served as the
standard non-human primate model of herpes simplex virus-
1 (HSV-1) infection because it is highly susceptible to HSV-1
encephalitis. Owl monkeys, however, are expensive, difﬁcult
to obtain, and difﬁcult to maintain in captivity, thus greatly
hampering the efﬁciency of preclinical gene therapy trials for
brain tumours using HSV-1-based vectors. Workers at Har-
vard Medical School have therefore recently compared the
susceptibility of the common marmoset (C. jacchus) with the
owl monkey in a model of intracerebral inoculation of
wildtype HSV-1 F-strain. The common marmosets consistent-
ly succumbed earlier to viral encephalitis than the owl
monkeys. The common marmoset is at least as susceptible
to intracerebral HSV-infection as the owl monkey and can
therefore serve as a valid and reliable experimental model for
the important preclinical safety tests of HSV-based therapeu-
tic viral vector constructs in the brain (127). The safe and
efﬁcient use of HSV-based vectors to deliver genes of
potentially therapeutic beneﬁt to the CNS requires their
effective disablement by the inactivation of viral genes
required for lytic growth. Viruses lacking functional genes
for ICP27 (which is required for growth in all cell types) and
ICP34.5 (which is required for growth in non-dividing cell
types) can efﬁciently deliver a marker gene to both rodent
and primate CNS with relatively minimal damage. Such
viruses paradoxically deliver genes at much higher efﬁciency
than the less disabled single mutant lacking ICP34.5 alone
and produce less damage in vivo. ICP27- and ICP34.5-viruses
thus offer a platform for the development of vectors which
are sufﬁciently safe for ultimate use in human gene therapy
(128).
Before autoimmune diseases (e.g. rheumatoid arthritis
and multiple sclerosis) in humans can be treated with gene
therapy, the safety and efﬁcacy of the used vectors must be
tested in valid experimental models. Monkeys, e.g. the rhesus
macaque or the common marmoset, are such models that are
now starting to be investigated (129). Non-human primate
models are useful to evaluate the safety and efﬁcacy of
therapeutic gene therapy, before the initiation of clinical trials
in humans. With this aim, Hibino et al. have focussed on a
Fig. 12. a Dorsal view of the equine intercarpal joint depicting areas of speciﬁc tissue sampling and the osteochondral fragment. b The design
of the in vivo OA model (120). Reprinted by permission from Macmillan Publishers Ltd: Gene Therapy (120), copyright (2002).
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small New World monkey, the common marmoset, as a target
preclinical model and its susceptibility to transduction by
retroviral vectors. Marmosets underwent transplantation with
autologous peripheral blood progenitor cells (PBPCs) trans-
duced with a retroviral vector carrying the multidrug resis-
tance 1 gene (MDR1). They demonstrated that this small
non-human primate is a useful model for the evaluation of
gene transfer methods targeting hematopoietic stem cells
(130).
Development of therapeutic agents against emerging
infectious diseases, e.g. severe acute respiratory syndrome
(SARS) viral infections, with siRNA exempliﬁes this power-
ful new technology. Potent siRNA inhibitors of SARS
coronavirus (SCV) in vitro were evaluated for efﬁcacy and
safety in a rhesus macaque (M. mulatta) SARS model using
clinically viable delivery while comparing three dosing
regimens which consistently showed siRNA-mediated anti-
SARS efﬁcacy by either prophylactic or therapeutic regimens.
The 10–40 mg/kg accumulated dosages of siRNA did not
show any sign of siRNA-induced toxicity. These results
suggest that a clinical investigation is warranted and illustrate
the prospects for siRNA to enable a massive reduction in
development time for new targeted therapeutic agents (131).
Huntington’s disease (HD) is a neurological disorder
caused by a genetic mutation in the IT15 gene with
characteristic progressive cell death in the striatum and
cortex, and accompanying declines in cognitive, motor, and
psychiatric functions. Animal models of HD provide insight
into disease pathology and the outcomes of therapeutic
strategies. The discovery, in 1993, of the huntingtin mutation
led to the creation of newer models that incorporate a similar
genetic defect. These models, which include transgenic and
knock-in rodents, are more representative of the HD
progression and pathology. An even more recent model that
uses a viral vector to encode the gene mutation in speciﬁc
areas of the brain may be useful in non-human primates, as it
is difﬁcult to produce genetic models in these species (132).
APPROPRIATE SELECTION OF ANIMAL MODELS
FOR POLYNUCLEIC ACID DELIVERY STUDIES
In our critical assessment as to which animal models are
more appropriate for certain types of polynucleic acid
delivery studies, and speciﬁcally with regard to “making the
appropriate selection”, it still does depend upon the disease
state under investigation. Whilst it is sure that the vast
majority of the animal models used in the laboratory are
mice and rats because of well rehearsed arguments: they are
small, easy to work with, inexpensive to keep, their genera-
tion time is short and they have large litters that can allow
controlled breeding programmes, however, in part because of
their short lifespan, murine models may fail to reproduce
authentically the human diseases process. Therefore, longitu-
dinal studies still need to be performed in large animal
models. Dog, cat, sheep and, in general, large animal models
have a longer lifespan, their physiological parameters, e.g.
their immune system, and their size make them more similar
to humans than the murine models. This does not address the
question of ethics, and certainly not of cost. The use of larger
animal models allows the disease states to be modelled more
accurately than rodent models, some of these diseases are
even naturally occurring e.g. gene therapy has been evaluated
in the brains of cats affected with α-mannosidosis (AMD) and
the RPE65−/− dog suffers from early and severe visual
impairment, similar to that seen in human Leber congenital
amaurosis (LCA). The pig can be used both for the
prevention of (porcine) foot-and-mouth disease and in
studying human heart disease. Horses naturally develop
arthritis. Even choosing to move to ﬁsh as an initial model
is, quite rightly, covered by the same ethical issues as murine
models. So we are not advocating zebraﬁsh as an insigniﬁcant
model, rather we are highlighting that some ﬁsh models may
enable useful biological data to be collected in certain
research areas, with regard to skin pigmentation, deafness,
and for cancer studies, and especially we stress that ﬁsh are
relevant for the ease of production of 200–600 embryos and
then looking in vivo with single cell resolution. The cellular
and genetic basis of disease (phenotypes at high resolution)
can be routinely studied in zebraﬁsh and medaka. We are
keenly aware of the importance of reﬁnement (in the
experiment), reduction (in the total number of animals
used), and replacement (of animals with cells lines or
computer modelling) (the 3Rs). We are not aware of any
published examples that did not translate from one model to
another. Animals are useful models for studying a treatment
hypothesis of a speciﬁc disease, but we always need to verify
that hypothesis in human clinical trials.
Humans and rodents, or indeed most animals (including
rabbits, dogs, cats, monkeys, apes) have roughly the same
number of nucleotides in their genomes, three billion bp, so a
similar number of genes. Whilst the number of human genes
without a clear (mouse) counterpart, and vice versa, may not
be signiﬁcantly larger than 1% of the total, nevertheless,
these novel genes may play an important role in determining
species-speciﬁc traits and functions (http://www.ornl.gov/sci/
techresources/human_genome/faq/compgen.shtml). In the
context of known inherited human diseases: a single nucleo-
tide change can lead to the inheritance of sickle cell disease,
cystic ﬁbrosis, or breast cancer. A single nucleotide change
can alter protein function deleteriously and major morpho-
logical differences can likewise occur. The same change, in
the same gene, but in different positions in the coding
sequence might do no harm at all. So, although we are very
similar to all other mammals, it is the subtle changes in the
30,000 genes, alternative splicing and post-translational mod-
iﬁcation (differing between species) that make (in part, not
forgetting the environment) for complexity.
ETHICAL CONSIDERATIONS USING POLYNUCLEIC
ACID THERAPY
In the very near future, as the techniques of gene therapy
and RNAi become simpler and more accessible, society will
need to deal with some complex ethical questions. One such
question is related to the possibility of genetically altering
human eggs or sperm, the reproductive cells that pass genes
on to future generations. Another question is related to the
potential for enhancing human capabilities, e.g. genetic
intervention to improve memory and intelligence. Although
both germ-line gene therapy and genetic enhancement have
the potential to produce beneﬁts, possible problems with
these procedures are correctly of widespread concern. Germ-
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line gene therapy would forever change the genetic makeup
of an individual’s descendants. Thus, the human gene pool
would be permanently affected. Although these changes
would presumably be for the better, an error in technology
or judgment could have far-reaching consequences. In the
case of genetic enhancement, there is concern that such
manipulation could become a luxury available only to the rich
and powerful. Some also fear that widespread use of this
technology could lead to new deﬁnitions of “normal” that
would exclude individuals who are, for example, of merely
average intelligence. Researchers on the Human Genome
Project (HGP) recognized that the information gained would
have profound implications for individuals, families, and
society. The Ethical, Legal, and Social Implications (ELSI)
Research Program was established in 1990 as part of the HGP
to address these issues. The ELSI Research Program
promotes basic and applied research on the implications of
genetic and genomic research for individuals, families, and
communities (http://www.ornl.gov/sci/techresources/Human_
Genome/medicine/genetherapy.shtml).
CONCLUSIONS
Most diseases that are currently viewed as candidates for
gene therapy are caused by mutations resulting in the absence
(malfunctioning) of a particular protein, e.g. enzyme deﬁ-
ciencies, missing ion channels, or are the result of dysregula-
tion/failure of controlled cell growth, i.e. cancer. In most gene
therapy studies, a “corrected” gene is inserted into the
genome to replace an “abnormal” disease-causing gene. The
genetic approach can also be used to reveal new targets for
therapies, as in our recent work on inﬂammation in CD1
strain mice uncovering a potential new target for anti-asthma
research (133). To understand fully and to treat genetic
diseases in patients, the use of authentic animal models is
required in studies that for ethical reasons and lack of
(human) volunteers are not possible. The species of animals
that are used in gene therapy studies are widespread as
highlighted in our review. They have been selected on the
basis that the animals had similar clinical signs to affected
humans, demonstrating similar genetic mechanisms underly-
ing the diseases in both species, or on their size (weight) and
metabolism. Thus, there are many excellent animal models
available to investigate target diseases using the new technol-
ogies of gene therapy and RNAi.
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